United Kingdom

Case Law, Enforcement, Infringement, Litigation, Patents, Procedure, Revocation, Sufficiency of disclosure, United Kingdom, Validity

(Bristows)/

On 9 October 2019, the Court of Appeal dismissed an appeal against the finding that a patent directed towards ceramic compounds was sufficient and allowed two procedural appeals on issues of liability. Anan Kasei and Rhodia (“Rhodia”) are respectively the proprietor and exclusive licensee of a patent for ceric oxide compounds for use in catalytic…

Case Law, CJEU, European Union, Pharma, SPC, United Kingdom

, (Vossius & Partner)/

One of the features that render the European Union’s Supplementary Protection Certificate (SPC) unique in comparison to similar legal instruments in other jurisdictions, including the United States and Japan, is that there is no legal provision expressly calling for any specific relationship or agreement between the patent proprietor (and SPC applicant) on the one hand,…

Brexit, European Union, Germany, Unitary Patent, United Kingdom, UPC

/ /5 Comments

‘Why Berlin can’t wait for Brexit in matters of UPC’, is the title of a recent article on the website of the German law firm Kather Augenstein. Main point: if the Federal Constitutional Court dismisses the constitutional complaint against the Unified Patent Court Agreement, the German government will have to finish the ratification procedure immediately,…

Germany, Unitary Patent, United Kingdom, UPC

/ /9 Comments

Even if the German constitutional complaint against the Unified Patent Court Agreement is dismissed, the German government will not proceed with ratification of the UPCA until the consequences of the Brexit are entirely clear. The German Justice Ministry made this clear in answer to questions of parliament. In a letter earlier this month it stated:…

Antibodies, Case Law, Inventive step, Novelty, United Kingdom

(Vossius & Partner)/

The case at hand concerned an application by Pfizer for Arrow-declarations in relation to its proposed launch of its bevacizumab product (it will be branded “Zirabev”) for the treatment of various cancers in combination with other drugs. Since Pfizer was unable to show a “useful purpose”, the complaint was dismissed. The mere prospect of using…

Case Law, European Union, Infringement, Injunction, Patents, SEP, United Kingdom

(Bristows)/

The Court of Appeal, overturning Birss J’s decision, decided that in the case of TQ Delta v ZyXEL, the answer was no. The facts of the case leading to this decision are somewhat unusual. TQ Delta asserted infringement of two patents declared essential to ITU-T standards. Following a trial in respect of liability, one of…

Antibodies, Case Law, European Union, Litigation, Novelty, Patents, Pharma, Pharmaceutical patent, Prior art, Sufficiency of disclosure, United Kingdom, Validity

(Bristows)/

Among the flurry of pre-summer vacation judgments coming from the Patents Court is one from Mr Justice Birss (17 July 2019), concerning the validity of Hoffman-La Roche’s patent EP (UK) 2 007 809. EP’809 is a formulation patent for the monoclonal antibody vedolizumab, marketed as Entyvio® and used to treat ulcerative colitis and Crohn’s disease….